Theriva biologics announces presentation of data from the phase 1b/2a clinical trial of syn-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients

Interim blinded safety and pharmacokinetic data to be presented at the congress of the european society of clinical microbiology and infectious diseases (escmid global) interim blinded safety and pharmacokinetic data to be presented at the congress of the european society of clinical microbiology and infectious diseases (escmid global)
TOVX Ratings Summary
TOVX Quant Ranking